ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $0 | -100.0% | 24 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 24 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | -75.0% | 24 | -64.2% | 0.00% | -100.0% |
| Q4 2020 | $4,000 | +33.3% | 67 | -11.8% | 0.00% | – |
| Q3 2020 | $3,000 | -40.0% | 76 | -32.1% | 0.00% | – |
| Q2 2020 | $5,000 | -96.3% | 112 | -96.5% | 0.00% | -100.0% |
| Q1 2020 | $136,000 | -49.8% | 3,245 | -48.6% | 0.01% | -35.3% |
| Q4 2019 | $271,000 | +22.6% | 6,311 | +2.2% | 0.02% | +13.3% |
| Q3 2019 | $221,000 | +2662.5% | 6,176 | +2051.9% | 0.02% | +1400.0% |
| Q2 2019 | $8,000 | -70.4% | 287 | -71.6% | 0.00% | -50.0% |
| Q1 2019 | $27,000 | -52.6% | 1,010 | -72.0% | 0.00% | -60.0% |
| Q4 2018 | $57,000 | +850.0% | 3,609 | +1222.0% | 0.01% | – |
| Q3 2018 | $6,000 | +100.0% | 273 | +120.2% | 0.00% | – |
| Q1 2018 | $3,000 | -25.0% | 124 | 0.0% | 0.00% | – |
| Q4 2017 | $4,000 | – | 124 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |